Keuangan Biogen Inc. (BIIB)
NASDAQ · Healthcare · Drug Manufacturers - General · Karyawan: 7.500 · CEO: Christopher A. Viehbacher
- Harga
- $253,62 +1,59%
- Kapitalisasi pasar
- $37,5 M
- Nilai perusahaan
- $44 M
- Laporan terakhir
- Q3 '26 diajukan 2026-10-28
- Laporan berikutnya
- 2027-02-05 Estimasi EPS: $2,85
Pendapatan (TTM)$10,3 M+3,1% vs tahun lalu4 kuartal terakhir; batang = tiap kuartal
Margin operasional (TTM)7,6%-16,8 poin vs tahun laluLaba operasional: $787 jt
Laba bersih (TTM)$348 jt-78,4% vs tahun laluSetelah pajak, termasuk keuntungan non-operasional
Arus kas bebas (TTM)$2,34 M+2,9% vs tahun laluCapex: -$95,6 jt
EPS dilusian (TTM)$2,34-78,7% vs tahun laluJumlah 4 kuartal terakhir
Kas neto-$6,5 M-147,1% vs tahun laluKas + investasi jangka pendek - utang
Valuasi & angka utama
- Kapitalisasi pasar
- $37,5 M EV $44 M
- Pendapatan
- $10,3 M 12 bulan terakhir
- Pertumbuhan pendapatan
- +8% Konsensus FY2026
- Margin laba
- 3,4% Laba bersih / pendapatan, TTM
- P/E
- 107,5× Forward 20,3× (FY2026)
- P/S
- 3,6× Harga / penjualan, TTM
- EV / EBITDA
- 30,4× TTM
- Arus kas bebas
- $2,34 M 12 bulan terakhir
- Laba bersih
- $348 jt 12 bulan terakhir
- Estimasi pendapatan
- $10,6 M Konsensus FY2026
- Laba
- 2027-02-05 Estimasi pendapatan: $2,58 M
- Dividen
- – Tanpa dividen
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-10-28): pendapatan melampaui 6,4%, EPS melampaui 31,7%Pendapatan $2,8 M vs $2,63 M yang diharapkan (+6,4%); EPS $2,62 vs $1,99 (+31,7%).
- Pertumbuhan pendapatan menguat: 14,2% yoyPendapatan Q3 '26: $2,8 M, rata-rata empat kuartal sebelumnya: -0,6%.
- Margin operasional 7,6% (TTM), dibanding tahun lalu: -16,8 poinLaba operasional tumbuh -67,8%, pendapatan tumbuh 3,1%.
- 171,3% dari laba sebelum pajak tergerus kerugian non-operasionalLaba sebelum pajak $290 jt vs laba operasional $787 jt (TTM). Kerugian dari kepemilikan saham dan pos sekali-pakai lainnya menekan laba bersih dan EPS - laba operasional adalah ukuran bisnis yang lebih bersih.
- Capex: 0,9% dari pendapatan (tahun lalu 1,8%)$95,6 jt diinvestasikan dalam 4 kuartal terakhir (-45,7% dibanding tahun sebelumnya). Arus kas bebas: $2,34 M = 673,2% dari laba bersih.
- Jumlah saham dilusian naik dalam setahun: 0,5%Saham dilusian pada Q3 '26: 148 jt, setahun sebelumnya: 147 jt.
- Utang neto: $6,5 MKas + investasi jangka pendek: $1,3 M, utang termasuk sewa: $7,8 M; tahun lalu utang neto: $2,63 M.
Kuartal terakhir: Q3 '26
Kuartal berakhir 2026-09-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q3 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $2,8 M | $2,45 M | +14,2% |
| Margin kotor | 73,3% | 64,3% | +9,0 poin |
| Laba operasional | $128 jt | $614 jt | -79,1% |
| Margin operasional | 4,6% | 25,0% | -20,4 poin |
| Laba bersih | -$20,6 jt | $467 jt | -104,4% |
| EPS dilusian | -$0,14 | $3,17 | -104,4% |
| Arus kas operasional | $641 jt | $1,27 M | -49,6% |
| Capex | $40,4 jt | $46,2 jt | -12,6% |
| Arus kas bebas | $600 jt | $1,23 M | -51,0% |
| R&D | $574 jt | $370 jt | +55,3% |
| Kompensasi berbasis saham | $81,5 jt | $75,3 jt | +8,2% |
Dilaporkan vs konsensus
2026-10-28| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| Pendapatan | $2,8 M | $2,63 M | +6,4% |
| EPS (basis konsensus) | $2,62 | $1,99 | +31,7% |
Dari laporan 2026-10-28 untuk Q3 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q3 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| MS Product Revenues | $919 jt | -13,4% | 40,0% | $3,76 M | -10,4% | |
| TYSABRI product | $437 jt | +1,2% | 19,0% | $1,73 M | +2,6% | |
| SPINRAZA | $461 jt | +23,2% | 20,0% | $1,59 M | -1,2% | |
| Fumarate | $274 jt | -28,4% | 11,9% | $1,14 M | -25,7% | |
| Interferon | $208 jt | -15,7% | 9,1% | $887 jt | -7,3% |
Pendapatan per wilayah
porsi dari total| Segmen | Q3 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| United States | $1,27 M | +35,3% | 60,6% | $3,22 M | -7,0% | |
| Non-US | $824 jt | -9,6% | 39,4% | $3,29 M | -14,0% |
Margin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas operasional
- $2,25 M
- Capex
- $95,6 jt
- Buyback
- $0
- Dividen
- $0
- Akuisisi
- -$6 jt
- Utang neto diterbitkan
- -$400 jt
- Kompensasi berbasis saham
- $141 jt
- Arus kas bebas
- $2,34 M
- Dikembalikan ke pemegang saham / FCF
- -0,0%
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | 107,5× | 20,4× | 13,2× – 32,3× |
| EV / EBITDA | 30,4× | 12,0× | 8,9× – 18,4× |
| EV / Penjualan | 4,3× | 3,6× | 2,7× – 4,4× |
| Harga / FCF | 16,0× | 19,5× | 8,9× – 35,2× |
| Harga / Nilai buku | 2,0× | 2,3× | 1,3× – 3,3× |
| Imbal hasil FCF | 6,2% | 7,0% | 2,8% – 11,3% |
| Imbal hasil modal yang diinvestasikan | 2,8% | 9,5% | 6,6% – 13,2% |
| Imbal hasil ekuitas | 1,9% | 12,3% | 7,1% – 22,7% |
Analis
Target konsensus $253,89 (+0,1%)
rentang $175,00 – $300,00 · peringkat Buy
Beli kuat0
Beli33
Tahan15
Jual1
Jual kuat0
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $10,6 M | +7,5% | $12,47 | +41,2% | 20,3× | 19 |
| FY2027 | $10,8 M | +2,0% | $16,27 | +30,5% | 15,6× | 20 |
| FY2028 | $11,1 M | +3,2% | $18,34 | +12,7% | 13,8× | 11 |
| FY2029 | $11,4 M | +3,1% | $20,38 | +11,1% | 12,4× | 4 |
| FY2030 | $11,7 M | +1,9% | $21,08 | +3,4% | 12,0× | 4 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 323 angka yang ditandai Biogen Inc. dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $430 jt | $413 jt | +4,2% | $432 jt | $424 jt | +1,8% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $1,34 M2025-12-31 | $1,4 M | -4,4% | $1,34 M | $1,4 M | -4,4% |
| Accounts Receivable, Allowance for Credit Loss, Current | $3,1 jt | $2,2 jt | +40,9% | $3 jt | $2,2 jt | +36,4% |
| Accrued Income Taxes, Noncurrent | $179 jt | $165 jt | +8,7% | $166 jt | $157 jt | +6,2% |
| Accrued Royalties, Current | $320 jt2025-09-30 | $179 jt | +79,2% | $221 jt2019-12-31 | $225 jt | -1,7% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $3,1 M | $2,87 M | +8,1% | $2,93 M | $2,67 M | +9,7% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$120 jt | -$215 jt | +44,0% | -$182 jt | -$136 jt | -33,6% |
| Additional Paid in Capital | $1,07 M | $798 jt | +34,2% | $863 jt | $569 jt | +51,6% |
| Advertising Expense | – | – | – | $71,9 jt | $66,8 jt | +7,6% |
| Amortization of Intangible Assets | $173 jt | $136 jt | +27,3% | $507 jt | $387 jt | +31,2% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $84,2 jt | $78,4 jt | +7,4% | – | – | – |
| APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition | – | – | – | $303 jt | $302 jt | +0,5% |
| Asset Impairment Charges | $0 | $0 | – | $0 | $0 | – |
| Assets | $32,1 M | $29,2 M | +9,7% | $29,4 M | $28 M | +5,0% |
| Assets, Current | $7,58 M | $8,94 M | -15,1% | $8,97 M | $7,46 M | +20,3% |
| Assets, Fair Value Disclosure | $861 jt | – | – | $3,69 M | $1,95 M | +89,1% |
| Buildings and Improvements, Gross | $2,14 M2025-12-31 | $1,96 M | +9,0% | $2,14 M | $1,96 M | +9,0% |
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | $400 rb | $5,6 jt | -92,9% | – | – | – |
| Business Combination, Contingent Consideration, Liability, Current | $152 jt | $149 jt | +2,6% | $291 jt2024-12-31 | – | – |
| Business Combination, Contingent Consideration, Liability, Noncurrent | $122 jt | $243 jt | -49,9% | $246 jt | $222 jt | +11,2% |
| Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred | $02026-05-14 | – | – | – | – | – |
| Cash and Cash Equivalents, Fair Value Disclosure | $628 jt | – | – | $2,23 M | $1,66 M | +34,1% |
| Cash Equivalents, at Carrying Value | $628 jt | $3,4 M | -81,5% | $2,23 M | $1,66 M | +34,1% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $1,3 M | $3,86 M | -66,2% | $3,01 M | $2,38 M | +26,7% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | $24,9 jt | $1,11 M | -97,8% | $532 jt | $1,39 M | -61,8% |
| Common Stock, Par or Stated Value Per Share | $0,00 | $0,00 | 0,0% | $0,00 | $0,00 | 0,0% |
| Common Stock, Shares Authorized | 1 M2025-12-31 | 1 M | 0,0% | 1 M | 1 M | 0,0% |
| Common Stock, Shares, Issued | 171 jt2025-12-31 | 170 jt | +0,6% | 171 jt | 170 jt | +0,6% |
| Common Stock, Shares, Outstanding | 147 jt2025-12-31 | 146 jt | +0,7% | 147 jt | 146 jt | +0,7% |
| Common Stock, Value, Issued | $100 rb | $100 rb | 0,0% | $100 rb2022-12-31 | $100 rb | 0,0% |
| Common Stock, Value, Outstanding | $100 rb2025-12-31 | $100 rb | 0,0% | $100 rb | $100 rb | 0,0% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | – | – | – | $0 | $0 | – |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$13,2 jt | $490 jt | -102,7% | $1,25 M | $1,65 M | -24,4% |
| Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | – | – | – | $1,25 M | $1,65 M | -24,4% |
| Construction in Progress, Gross | $163 jt2025-12-31 | $308 jt | -47,1% | $163 jt | $308 jt | -47,1% |
| Construction Payable | $89,1 jt2025-09-30 | – | – | $78 jt2019-12-31 | $125 jt | -37,7% |
| Cost of Goods and Services Sold | $748 jt | $674 jt | +11,0% | $2,4 M | $2,31 M | +4,1% |
| Costs and Expenses | $2,81 M | $1,98 M | +42,3% | $8,33 M | $7,77 M | +7,3% |
| Current Federal Tax Expense (Benefit) | – | – | – | $10,1 jt | $449 jt | -97,8% |
| Current Foreign Tax Expense (Benefit) | – | – | – | -$155 jt | -$67,5 jt | -130,2% |
| Current Income Tax Expense (Benefit) | – | – | – | -$98 jt | $432 jt | -122,7% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $47,3 jt | $50,5 jt | -6,3% |
| Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $281 jt2025-12-31 | $272 jt | +3,3% | $281 jt | $272 jt | +3,3% |
| Debt Securities, Available-for-sale | $1,37 M2026-03-31 | – | – | $1,24 M | – | – |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $02026-03-31 | – | – | $200 rb | – | – |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $2 jt2026-03-31 | – | – | $0 | – | – |
| Debt Securities, Available-for-sale, Amortized Cost | $1,37 M2026-03-31 | – | – | $1,24 M | – | – |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $456 jt2026-03-31 | – | – | $419 jt | – | – |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One | $901 jt2026-03-31 | – | – | $807 jt | – | – |
| Debt Securities, Available-for-sale, Current | $0 | $97,6 jt | -100,0% | $807 jt | $0 | – |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $455 jt2026-03-31 | – | – | $420 jt | – | – |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | $900 jt2026-03-31 | – | – | $807 jt | – | – |
| Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost | $1,37 M2026-03-31 | – | – | $1,24 M | – | – |
| Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value | $1,37 M2026-03-31 | – | – | $1,24 M | – | – |
| Debt Securities, Available-for-sale, Noncurrent | $0 | – | – | $432 jt | $0 | – |
| Debt Securities, Available-for-sale, Realized Gain | $0 | $0 | – | $0 | $0 | – |
| Debt Securities, Available-for-sale, Realized Loss | $0 | $0 | – | $0 | $0 | – |
| Debt, Current | $02025-12-31 | $1,75 M | -100,0% | $0 | $1,75 M | -100,0% |
| Decrease in Unrecognized Tax Benefits is Reasonably Possible | $35 jt2025-09-30 | $55 jt | -36,4% | $45 jt2024-12-31 | $20 jt | +125,0% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | $346 jt | -$155 jt | +324,0% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, estimasi: Financial Modeling Prep. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
Data per 2026-11-02